Form 4: STERIS Executive Kenneth Kohler Reports Equity Grant

STERIS plc SVP & GM Kenneth E. Kohler acquired 2,199 ordinary shares and 7,668 stock options as part of an equity compensation plan.

Summary

• Kenneth E. Kohler, SVP & GM of Applied Sterilization Technologies (AST), received an equity grant on June 2, 2026.
• The transaction included the acquisition of 2,199 ordinary shares and 7,668 employee stock options.
• 66 shares were withheld to satisfy tax obligations related to the vesting of restricted shares.
• Following these transactions, the reporting person holds 11,666 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral for the stock price.

Positives

• Alignment of executive interests with shareholders through equity-based compensation.
• Retention of key management personnel through multi-year vesting schedules for restricted shares and options.

Negatives

• Dilutive effect of new equity grants on existing shareholders.

Risks

• Market price volatility affecting the value of stock options.
• Potential for future tax withholding requirements upon the vesting of remaining restricted shares.

Future Outlook

The filing outlines a multi-year vesting schedule for restricted shares through June 2029 and stock options through June 2030, indicating long-term retention of the executive.

Industry Context

StockSavvy.ai notes that equity grants for senior executives in the medical technology sector are standard practice for aligning leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units and stock options is consistent with compensation structures at peer medical device companies like Baxter International and Becton Dickinson.
• The vesting schedule of 4 years is standard for executive compensation in the S&P 500.

Stakeholder Impact

• Shareholders: Minor dilution from new equity issuance.
• Executive: Increased financial stake in company performance.

Next Steps

• Vesting of restricted shares on June 3, 2026.
• Exercise of stock options beginning June 2, 2027.

Key Dates

Keywords

STERIS, STE, Form 4, Insider Trading, Equity Compensation, Stock Options